基于T细胞功能相关基因与血浆蛋白的急性髓系白血病生存预测优化
研究从公共数据库提取1611例急性髓系白血病(AML)患者的RNA矩阵数据,构建并验证了一个八基因T细胞功能相关特征。该特征在高危组与低危组的五年生存率分别为6%-23%与42%-58%(所有p值<0.001),高危评分独立预测较短生存(死亡风险比范围1.28-2.59)。将基因特征与2017年欧洲白血病网(ELN)分类结合,五年AUROC从0.76提高至0.82(p<0.001)。
要点
- 八基因T细胞功能相关特征在训练和验证队列中五年AUROC为0.67-0.76。
- 高危组五年生存率6%-23%,低危组42%-58%(所有p值<0.001)。
- 高危评分独立预测较短生存,死亡风险比范围1.28-2.59。
核心结论
- T细胞功能相关风险评分可补充现有AML预后模型。
- 将基因表达特征与2017年ELN分类结合,五年AUROC从0.76提高至0.82(p<0.001)。
研究设计与样本
- 从公共数据库提取1611例AML患者的RNA矩阵数据,分为一个训练队列和三个验证队列。
- 使用随机生存森林变量搜寻算法构建八基因T细胞功能相关特征。
- 在包含88份治疗前血浆样本的真实世界队列中验证基因识别的准确性。
主要发现
- 模型在训练和验证队列中五年AUROC为0.67-0.76。
- 高危组五年生存率为6%-23%,低危组为42%-58%(所有p值<0.001)。
- 多变量分析中,高危评分独立预测较短生存,死亡风险比范围1.28-2.59。
- 基因集富集分析显示高危组中免疫抑制通路相关基因显著富集。
- 单细胞RNA测序分析显示特征中大多数基因在白血病细胞中转录。
关键数值与推荐
- 使用最佳截断值将特征分为高风险和低风险评分。
- 高危组五年生存率6%-23%,低危组42%-58%(所有p值<0.001)。
- 高危评分死亡风险比范围1.28-2.59。
- 基因特征联合2017年ELN分类五年AUROC为0.82,单独ELN分类为0.76(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interactions between acute myeloid leukaemia (AML) cells and immune cells are postulated to corelate with outcomes of AML patients. However, data on T-cell function-related signature are not included in current AML survival prognosis models. We examined data of RNA matrices from 1611 persons with AML extracted from public databases arrayed in a training and three validation cohorts. We developed an eight-gene T-cell function-related signature using the random survival forest variable hunting algorithm. Accuracy of gene identification was tested in a real-world cohort by quantifying cognate plasma protein concentrations. The model had robust prognostic accuracy in the training and validation cohorts with five-year areas under receiver-operator characteristic curve (AUROC) of 0.67-0.76. The signature was divided into high- and low-risk scores using an optimum cut-off value. Five-year survival in the high-risk groups was 6%-23% compared with 42%-58% in the low-risk groups in all the cohorts (all p values <0.001). In multivariable analyses, a high-risk score independently predicted briefer survival with hazard ratios of death in the range 1.28-2.59. Gene set enrichment analyses indicated significant enrichment for genes involved in immune suppression pathways in the high-risk groups. Accuracy of the gene signature was validated in a real-world cohort with 88 pretherapy plasma samples. In scRNA-seq analyses most genes in the signature were transcribed in leukaemia cells. Combining the gene expression signature with the 2017 European LeukemiaNet classification significantly increased survival prediction accuracy with a five-year AUROC of 0.82 compared with 0.76 (p < 0.001). Our T-cell function-related risk score complements current AML prognosis models.
引用
- Wang Y, Chen S, Chi P, et al. Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins. Br J Haematol. 2022. PMID: 36113865. doi:10.1111/bjh.18453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。